/
We are a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of retinal diseases. We are developing KIO-301, with an initial focus on patients with later stages of vision loss due to retinitis pigmentosa (collectively including any and all sub-forms, "RP").
$2.63
+$0.08 (+3.14%)
EOD Jul 17, 2026
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Free cash flow declined 218% versus the prior year, cash generation momentum has weakened. ROIC dropped from 15.27% to -47.91%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$11M
▼ -401.4% YoY
Op. Margin
—
ROIC
-53.97%
▼ -63.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▼ -217.8% YoY
Op. Cash Flow (TTM)
-$10M
▼ -216.4% YoY
Net Debt
-$13M
Net Cash Position
Cash & Equiv.
$14M
Continue Research
Kiora Pharmaceuticals (KPRX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Kiora Pharmaceuticals scores 20/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Kiora Pharmaceuticals scores 20 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -54.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh KPRX's valuation and scores 20/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.